Novo Nordisk’s Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.
Novo Nordisk’s Ozempic already is threatening to disrupt a range of industries via its weight-loss benefits. Now it looks set to threaten companies which treat kidney failure.
However, scientists are still working on other uses for the drugs. Novo Nordisk said late Tuesday that Ozempic showed sufficient success in a trial for kidney failure in diabetes patients that it would stop the study early.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion companyHow Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Lire la suite »
Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Lire la suite »
Stock movers: Novo Nordisk, Fresenius Medical Care, DaVita, Thor IndustriesNovo Nordisk, Thor Industries, Silk Road Medical, Fresenius Medical Care, and DaVita all showed stock price movement in pre-market trading
Lire la suite »
Tamra Judge fires back at 'disgusting' theory that Ozempic use led to intestinal obstructionTamra Judge hospitalized for intestinal obstruction: ‘Praying I won’t need surgery’
Lire la suite »
Ozempic and Wegovy aren’t affecting PepsiCo’s business much — but this trend isStock sold off last week after Walmart said Wegovy and Ozempic were leading customers to buy fewer groceries and cut back on calories
Lire la suite »
Ozempic Won't Kill Americans' Taste for Sugary SnacksInvestors' fears that the new weight-loss drugs will hamstring Big Food companies are overblown.
Lire la suite »